Stroke: Combination of cilostazol and clopidogrel can significantly reduce the risk of recurring stroke

Antiplatelet therapy is the most basic treatment method to prevent secondary stroke in patients with non-myocardial infarction and ischemic stroke

Combination therapy with aspirin and clopidogrel has a stronger inhibitory effect on platelet function than using any of these drugs alone.

Cilostazol selectively inhibits phosphodiesterase 3 and CSPS2 (Cilostazol Stroke Prevention Study 2).

In the CSPS.

In this way, Haruhiko Hoshino and others at Tokyo Saiseikai Central Hospital in Japan analyzed the effectiveness and safety of cilostazol and clopidogrel combined treatment in patients enrolled in the CSPS.

The CSPS.

Patients were randomly assigned to receive monotherapy or DAPT with cilostazol, and were followed up for 0.

A total of 763 patients taking aspirin and 1,116 patients taking clopidogrel were included in the intention-to-treat analysis

Although the clopidogrel group had more risk factors than the aspirin group, the main efficacy and safety results were not significantly different between the two groups

In the clopidogrel group, the incidence of the primary endpoint was 2.

There was no significant difference in safety results between the groups (0.

The important significance of this study lies in the discovery: the combined use of cilostazol and clopidogrel can significantly reduce the recurrence rate of ischemic stroke in non-myocardial infarction high-risk patients without increasing the risk of bleeding